Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.

The Prostate Pub Date : 2022-05-01 Epub Date: 2022-02-21 DOI:10.1002/pros.24312
Benedikt Hoeh, Christoph Würnschimmel, Rocco Simone Flammia, Benedikt Horlemann, Gabriele Sorce, Francesco Chierigo, Zhe Tian, Fred Saad, Markus Graefen, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F Shariat, Derya Tilki, Luis A Kluth, Philipp Mandel, Felix K H Chun, Pierre I Karakiewicz
{"title":"Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.","authors":"Benedikt Hoeh,&nbsp;Christoph Würnschimmel,&nbsp;Rocco Simone Flammia,&nbsp;Benedikt Horlemann,&nbsp;Gabriele Sorce,&nbsp;Francesco Chierigo,&nbsp;Zhe Tian,&nbsp;Fred Saad,&nbsp;Markus Graefen,&nbsp;Michele Gallucci,&nbsp;Alberto Briganti,&nbsp;Carlo Terrone,&nbsp;Shahrokh F Shariat,&nbsp;Derya Tilki,&nbsp;Luis A Kluth,&nbsp;Philipp Mandel,&nbsp;Felix K H Chun,&nbsp;Pierre I Karakiewicz","doi":"10.1002/pros.24312","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>No North-American study tested the survival benefit of chemotherapy in de novo metastatic prostate cancer according to race/ethnicity. We addressed this void.</p><p><strong>Methods: </strong>We identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results database (2014-2015). Separate and specific Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed versus chemotherapy-naïve patients in four race/ethnicity groups: Caucasian versus African-American versus Hispanic/Latino vs Asian. Race/ethnicity specific propensity score matching was applied. Here, additional landmark analysis was performed.</p><p><strong>Results: </strong>Of 4232 de novo metastatic prostate cancer patients, 2690 (63.3%) were Caucasian versus 783 (18.5%) African-American versus 504 (11.8%) Hispanic/Latino versus 257 (6.1%) Asian. Chemotherapy rates were: 21.3% versus 20.8% versus 21.0% versus 20.2% for Caucasians versus African-Americans versus Hispanic/Latinos versus Asians, respectively. At 30 months of follow-up, overall survival rates between chemotherapy-exposed versus chemotherapy-naïve patients were 61.5 versus 53.2% (multivariable hazard ratio [mHR]: 0.76, 95 confidence interval [CI]: 0.63-0.92, p = 0.004) in Caucasians, 55.2 versus 51.6% (mHR: 0.76, 95 CI: 0.54-1.07, p = 0.11) in African-Americans, 62.8 versus 57.0% (mHR: 1.11, 95 CI: 0.73-1.71, p = 0.61) in Hispanic/Latinos and 77.7 versus 65.0% (mHR: 0.31, 95 CI: 0.11-0.89, p = 0.03) in Asians. Virtually the same findings were recorded after propensity score matching within each race/ethnicity group.</p><p><strong>Conclusions: </strong>Caucasian and Asian de novo metastatic prostate cancer patients exhibit the greatest overall survival benefit from chemotherapy exposure. Conversely, no overall survival benefit from chemotherapy exposure could be identified in either African-Americans or Hispanic/Latinos. Further studies are clearly needed to address these race/ethnicity specific disparities.</p>","PeriodicalId":501684,"journal":{"name":"The Prostate","volume":" ","pages":"676-686"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.24312","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: No North-American study tested the survival benefit of chemotherapy in de novo metastatic prostate cancer according to race/ethnicity. We addressed this void.

Methods: We identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results database (2014-2015). Separate and specific Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed versus chemotherapy-naïve patients in four race/ethnicity groups: Caucasian versus African-American versus Hispanic/Latino vs Asian. Race/ethnicity specific propensity score matching was applied. Here, additional landmark analysis was performed.

Results: Of 4232 de novo metastatic prostate cancer patients, 2690 (63.3%) were Caucasian versus 783 (18.5%) African-American versus 504 (11.8%) Hispanic/Latino versus 257 (6.1%) Asian. Chemotherapy rates were: 21.3% versus 20.8% versus 21.0% versus 20.2% for Caucasians versus African-Americans versus Hispanic/Latinos versus Asians, respectively. At 30 months of follow-up, overall survival rates between chemotherapy-exposed versus chemotherapy-naïve patients were 61.5 versus 53.2% (multivariable hazard ratio [mHR]: 0.76, 95 confidence interval [CI]: 0.63-0.92, p = 0.004) in Caucasians, 55.2 versus 51.6% (mHR: 0.76, 95 CI: 0.54-1.07, p = 0.11) in African-Americans, 62.8 versus 57.0% (mHR: 1.11, 95 CI: 0.73-1.71, p = 0.61) in Hispanic/Latinos and 77.7 versus 65.0% (mHR: 0.31, 95 CI: 0.11-0.89, p = 0.03) in Asians. Virtually the same findings were recorded after propensity score matching within each race/ethnicity group.

Conclusions: Caucasian and Asian de novo metastatic prostate cancer patients exhibit the greatest overall survival benefit from chemotherapy exposure. Conversely, no overall survival benefit from chemotherapy exposure could be identified in either African-Americans or Hispanic/Latinos. Further studies are clearly needed to address these race/ethnicity specific disparities.

化疗对转移性前列腺癌的影响根据种族/民族分组。
背景:没有北美研究根据种族/民族测试化疗对新发转移性前列腺癌的生存获益。我们解决了这个空白。方法:我们在监测、流行病学和最终结果数据库(2014-2015)中确定了新发转移性前列腺癌患者。单独和特定的Kaplan-Meier图和Cox回归模型测试了化疗暴露患者与chemotherapy-naïve患者在四个种族/民族组中的总体生存差异:高加索人与非裔美国人,西班牙裔/拉丁裔与亚洲人。采用种族/民族特定倾向评分匹配。在这里,进行了额外的里程碑分析。结果:在4232例新发转移性前列腺癌患者中,2690例(63.3%)为白种人,783例(18.5%)为非裔美国人,504例(11.8%)为西班牙裔/拉丁裔,257例(6.1%)为亚裔。化疗率分别为:21.3%对20.8%,21.0%对20.2%,白人对非洲裔美国人对西班牙裔/拉丁裔美国人对亚洲人。在30个月的随访中,整体存活率chemotherapy-exposed与chemotherapy-naive患者61.5与53.2%之间(多变量风险比(mHR): 0.76, 95可信区间[CI]: 0.63 - -0.92, p = 0.004)在白种人,51.6%和55.2 (mHR: 0.76, 95 CI: 0.54 - -1.07, p = 0.11)在非裔美国人,57.0%和62.8 (mHR: 1.11, 95 CI: 0.73 - -1.71, p = 0.61)在西班牙/拉丁裔和77.7和65.0% (mHR: 0.31, 95 CI: 0.11 - -0.89, p = 0.03)的亚洲人。在每个种族/族裔群体的倾向得分匹配之后,几乎记录了相同的发现。结论:高加索和亚洲新发转移性前列腺癌患者从化疗暴露中表现出最大的总体生存获益。相反,在非裔美国人或西班牙裔/拉丁裔美国人中,没有发现化疗暴露的总体生存益处。显然需要进一步的研究来解决这些种族/民族特有的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书